<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548468</url>
  </required_header>
  <id_info>
    <org_study_id>15D.237</org_study_id>
    <nct_id>NCT02548468</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma</brief_title>
  <official_title>A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and the best dose of donor lymphocyte infusion
      when given together with reduced intensity conditioning regimen before partially matched
      donor stem cell transplant in treating patients with stage IIB-IV mycosis fungoides or Sezary
      syndrome. Giving chemotherapy and low-dose total-body irradiation followed by high-dose
      cyclophosphamide before a donor peripheral blood stem cell transplant helps stop the growth
      of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer
      cells. Sometimes the transplanted cells from a donor can make an immune response against the
      body's normal cells (called graft-versus-host disease). Removing the T-cells from the donor
      cells and giving them before transplant may stop this from happening. Additionally, giving
      tacrolimus and mycophenolate mofetil before and after transplant may also stop this from
      happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTVES:

      I. To evaluate regimen related toxicity, engraftment and graft versus host disease (GVHD) in
      the first 100 days with new reduced intensity haploidentical regimen protocol, including
      fludarabine (fludarabine phosphate), low dose total body irradiation, and cyclophosphamide.

      II. To determine an effective donor lymphocyte infusion (DLI) dose that provides successful
      engraftment without causing GVHD.

      SECONDARY OBJECTIVES:

      I. To assess myeloid and lymphoid engraftment rates of patients undergoing treatment on this
      regimen.

      II. To determine the incidence and severity of GVHD in patients undergoing treatment on this
      regimen using a combination of tacrolimus and mycophenolate mofetil (MMF) as GVHD
      prophylaxis.

      III. To examine progression free survival and overall survival in patients with cytotoxic
      T-cell lymphoma (CTCL) undergoing treatment on this regimen.

      IV. To assess the pace of lymphoid recovery in this patient population.

      OUTLINE: This is a phase I, dose-escalation study of DLI.

      REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate intravenously (IV)
      over 30 minutes on days -11 to -8 and undergo total body irradiation twice daily (BID) on day
      -7. Patients also receive donor cluster of differentiation (CD)3+ enriched T lymphocyte
      infusion on day -6 and high-dose cyclophosphamide IV over 2 hours on days -3 to -2.

      TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant (PBSCT) on day
      0.

      GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV with taper (drug wean)
      by day 60 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD.

      After completion of treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date type="Actual">November 20, 2015</start_date>
  <completion_date type="Actual">March 16, 2017</completion_date>
  <primary_completion_date type="Actual">January 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of regimen-related toxicities</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
    <description>Estimate of dose-specific rates of toxicity will be presented with corresponding confidence intervals using the exact method. The method of Atkinson and Brown will be used for any rate related to definition of dose limiting toxicity, due to two-stage sampling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate for hematopoietic engraftment</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
    <description>Estimate of dose-specific rate for engraftment will be presented with corresponding confidence intervals using the exact method. The method of Atkinson and Brown will be used for any rate related to definition of dose limiting toxicity, due to two-stage sampling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate for immune reconstitution</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
    <description>Estimate of dose-specific rate for immune reconstitution will be presented with corresponding confidence intervals using the exact method. The method of Atkinson and Brown will be used for any rate related to definition of dose limiting toxicity, due to two-stage sampling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of GVHD</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of DLI, determined according to dose limiting toxicities</measure>
    <time_frame>day -4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myeloid engraftment rate</measure>
    <time_frame>Up to 6 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphoid engraftment rate</measure>
    <time_frame>Up to 6 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of GVHD using tacrolimus and mycophenolate mofetil prophylaxis</measure>
    <time_frame>Up to 6 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 6 months post-transplant</time_frame>
    <description>Progression free survival will be estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 6 months post-transplant</time_frame>
    <description>OS will be estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of lymphoid recovery</measure>
    <time_frame>Up to 6 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>All estimates of dose-specific rates (e.g., toxicity) will be presented with corresponding confidence intervals using the exact method. The method of Atkinson and Brown will be used for any rate related to definition of dose limiting toxicity, due to two-stage sampling.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cutaneous T-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides and Sezary Syndrome</condition>
  <condition>Stage IIB Mycosis Fungoides and Sezary Syndrome</condition>
  <condition>Stage IIIA Mycosis Fungoides and Sezary Syndrome</condition>
  <condition>Stage IIIB Mycosis Fungoides and Sezary Syndrome</condition>
  <condition>Stage IVA Mycosis Fungoides and Sezary Syndrome</condition>
  <condition>Stage IVB Mycosis Fungoides and Sezary Syndrome</condition>
  <arm_group>
    <arm_group_label>Reduced Intensity Conditioning, DLI, PBSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -11 to -8 and undergo total body irradiation BID on day -7. Patients also receive donor CD3+ enriched T lymphocyte infusion on day -6 and high-dose cyclophosphamide IV over 2 hours on days -3 to -2.
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV with taper (drug wean) by day 60 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Reduced Intensity Conditioning, DLI, PBSCT</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Reduced Intensity Conditioning, DLI, PBSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T Cell-Depleted Donor Lymphocyte Infusion</intervention_name>
    <description>Undergo donor CD3+ enriched T lymphocyte infusion</description>
    <arm_group_label>Reduced Intensity Conditioning, DLI, PBSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Reduced Intensity Conditioning, DLI, PBSCT</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>CP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic HSC transplant</description>
    <arm_group_label>Reduced Intensity Conditioning, DLI, PBSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT</description>
    <arm_group_label>Reduced Intensity Conditioning, DLI, PBSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Reduced Intensity Conditioning, DLI, PBSCT</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Reduced Intensity Conditioning, DLI, PBSCT</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stage IIB-IV mycosis fungoides and sezary syndrome who have failed at least one
             standard systemic therapy or are not candidates for standard therapy.

          2. Patient should have a responsive skin disease including complete remission (CR) and
             partial remission (PR) (close to CR; 75%-99% clearance of skin disease from baseline
             without new tumors (T3) in patients with T1, T2 or T4 only skin disease) and should
             not have visceral organ or lymph node involvement prior to transplantation.

          3. Patients must have a related donor who is a two or more allele mismatch at the HLA-A;
             B; C; DR and DQ loci. Patients who have sibling donors with a one antigen mismatch due
             to recombination will not be enrolled in this protocol.

          4. Patients must have adequate organ function:

               -  Left Ventricular Ejection Fraction (LVEF) of &gt;50%

               -  Carbon Monoxide Diffusing Capacity (DLCO) &gt;50% of predicted corrected for
                  hemoglobin

               -  Adequate liver function as defined by a serum bilirubin &lt;2.0 (unless hemolysis or
                  Gilbert disease), Aspartate aminotransferase (AST) or Alanine aminotransferase
                  (ALT) &lt; 2.5 X upper limit of normal

               -  Creatinine clearance of &gt; 60 ml/min

          5. Performance status &gt; 80% (Karnofsky)

          6. Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) &lt;5 for age &lt;
             65, HCT-CI &lt;4 for age &gt;65

          7. Patients must be willing to use contraception if they have childbearing potential

          8. Able to give informed consent, or their legally authorized representative can give
             informed consent.

        Exclusion Criteria:

          1. Performance status of &lt; 80% (Karnofsky)

          2. HIV positive

          3. Active involvement of the central nervous system with malignancy

          4. Psychiatric disorder that would preclude patients from signing an informed consent

          5. Pregnancy, or unwillingness to use contraception if they are have childbearing
             potential.

          6. Patients with life expectancy of &lt; 6 months for reasons other than their underlying
             hematologic/oncologic disorder or complications there from.

          7. Patients who have received alemtuzumab within 8 weeks of transplant admission, or who
             have recently received horse or rabbit anti-thymocyte globulin (ATG) and have ATG
             levels of &gt; 2 Î¼gm/ml.

          8. Patients who cannot receive cyclophosphamide

          9. Patients with evidence of another malignancy (exclusive of a skin cancer that requires
             only local treatment);

               -  Patients with prior malignancies diagnosed&gt; 5 years ago without evidence of
                  disease are eligible.

               -  Patients with prior malignancy treated &lt; 5 years ago but have a life expectancy
                  of &gt; 5 years for that malignancy are eligible.

         10. Uncontrolled active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Onder Alpdogan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Jefferson University Hospitals</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

